

Technical Data Sheet

Human PD1 Protein (C-Fc)

Catalog Number: 803201, 803202

Size: 25 ug, 100 ug

Target Name: PD1, PDCD1, CD279, SLEB2

Regulatory Status: RUO

Product Details

Application: ELISA, BLI

Format: Liquid, Purified

Expression Host: HEK293

Species: Human

Sources: Human PD-1 protein (NP_005009.2) (Leu25-Gln167) with C-terminus Fc tag is expressed in HEK293 cells.

Accession Number: Q15116

Molecular Weight: The protein has a predicted molecular weight of 42 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE.

Affinity Tag: C-Fc

Purity: >95% based on SDS-PAGE under reducing condition

Formulation: 1xPBS buffer, pH7.4, 0.22 µm filtered

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.


Background Information

Programmed Death-1 receptor (PD-1, also known as CD279) is a type I transmembrane protein and an immunoregulatory receptor of the CD28/CTLA-4 family. It is expressed on activated T cells, B cells, monocytes, dendritic cells, and some thymocytes. PD-1 binds to ligands PD-L1 and PD-L2, transmitting co-inhibitory signals that suppress T-cell activation, proliferation, cytokine production, and cytotoxic activity by dephosphorylating key signaling molecules. This mechanism promotes immune tolerance and prevents autoimmunity but is exploited by tumors to evade immune surveillance, as many tumors upregulate PD-L1. When tumor-expressed PD-L1 engages PD-1 on immune cells, it blocks T-cell activation and promotes immune exhaustion. Monoclonal antibodies targeting the PD-1/PD-L1 pathway have revolutionized cancer therapy by releasing this immune brake, enhancing anti-tumor immunity and leading to tumor regression in many cancers. Examples

include nivolumab and pembrolizumab. This immunotherapy approach is now a major focus in oncology, offering a powerful tool to boost the immune system against cancer and reshape treatment paradigms.

Product Data

803201/803202 image 1



Human PD-1 protein (C-Fc) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.

Human PD-1 protein (C-Fc) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%?